Genvor Inc: assigns rights to 9,000 antimicrobial peptides

What happened
Genvor Inc filed an 8-K reporting that on Oct 22, 2026 the company entered into an Intellectual Property Assignment Agreement with Dr. Jesse Jaynes, Ph.D., one of the company’s founders, directors, and the company’s Chief Scientific Officer. Under the agreement, Dr. Jaynes assigned to the company the rights to the synthetic and designed peptide sequences, including the approximately 9,000 antimicrobial peptides referred to in the company’s Annual Report on Form 10-K for the fiscal year ended Sep 30, 2025, together with associated design, screening, activity, formulation and validation data and any unpublished design notes, rules or selection criteria provided to or used by the company in its research, development and commercialization programs.

Key details

• Agreement date reported: Oct 22, 2026.
• Party assigning rights: Dr. Jesse Jaynes, Ph.D. (founder, director, and chief scientific officer).
• Scope: synthetic and designed peptide sequences, including approximately 9,000 antimicrobial peptides, plus associated data and unpublished design notes, rules or selection criteria.
• The filing states the summary is qualified in its entirety by reference to the full text of the Assignment Agreement.

Why it may matter
The item reported is Item 1.01 (Entry into a material definitive agreement), which covers the company’s acquisition of intellectual property rights described in the Assignment Agreement. This filing does not show why the insider traded or why the company acted.